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Abstract 1 
Background: Early clinical trials of a Clostridium difficile toxoid vaccine show efficacy in 2 
preventing C. difficile infection (CDI). The optimal patient group to target for vaccination 3 
programmes remains unexplored. This study performed a model-based evaluation of the 4 
effectiveness of different CDI vaccination strategies, within the context of existing infection 5 
prevention and control strategies such as antimicrobial stewardship. 6 
Methods: An individual-based transmission model of CDI in a high-risk hospital setting was 7 
developed. The model incorporated data on patient movements between the hospital, and 8 
catchment populations from the community and long-term care facilities (LTCF), using 9 
English national and local level data for model-parameterisation. We evaluated vaccination 10 
of: 1) discharged patients who had an CDI-occurrence in the ward; 2) LTCF-residents; 3) 11 
Planned elective surgical admissions and 4) All three strategies combined. 12 
Results: Without vaccination, 10.9 [Interquartile range: 10.0 – 11.8]  patients per 1000 ward 13 
admissions developed CDI, of which 31% were ward-acquired. Immunising all three patient 14 
groups resulted in a 43% [42 – 44], reduction of ward-onset CDI on average. Among the 15 
strategies restricting vaccination to one target group, vaccinating elective surgical patients 16 
proved most effective (35% [34 – 36] reduction), but least efficient, requiring 146 [133 – 17 
162] courses to prevent one ICU-onset case. Immunising LTCF residents was most efficient, 18 
requiring just 13 [11 – 16] courses to prevent one case, but considering this only comprised a 19 
small group of our hospital population, it only reduced ICU-onset CDI by 9% [8 – 11]. 20 
Vaccination proved most efficient when ward-based transmission rates and antimicrobial 21 
consumption were high.  22 
Conclusions: Strategy success depends on the interaction between hospital and catchment 23 
populations, and importantly, consideration of importations of CDI from outside the hospital 24 
  2 
which we found to substantially impact hospital dynamics. Vaccination may be most 25 
desirable in settings or patient groups where levels of broad-spectrum antimicrobial use are high 26 
and difficult to reduce. 27 
28 
  3 
Introduction 29 
Clostridium difficile infection (CDI) is a source of considerable morbidity and 30 
mortality and places a substantial burden on healthcare systems[1]. Though traditionally 31 
viewed as a healthcare-associated bacteria, intensivied surveillance reveal increasing reports 32 
of CDI cases without recent hospitalisation [2]. Antimicrobial stewardship, mandatory 33 
surveillance, and enhanced infection prevention and control measures (IPC) to prevent C. 34 
difficile transmission have been implemented in hospitals and the community with success in 35 
some countries[3]. Nonetheless there remains the need to prevent CDI in settings and 36 
vulnerable patient groups where strict antimicrobial stewardship or IPC is not possible or 37 
desirable.   38 
Three vaccines targeting the main virulence factors of C. difficile (TcdA and TcdB) 39 
are currently under development and have showed promising results in  phase I and II clinical 40 
trials [4–9], with the first Phase III trials now underway[10]. These vaccines induce an IgG 41 
antibody response against TcdA and TcdB and therefore aim to prevent the development of 42 
symptomatic disease in exposed individuals[e.g. 2,6,7]. A successful vaccine that prevented 43 
primary or recurrent onset of CDI would reduce morbidity and mortality directly in the 44 
vaccinated individual. It could also have a population-level effect by reducing the spread of 45 
infectious spores from infected individuals into the environment, and thus preventing onward 46 
transmission of the bacteria. Current evidence, based on highly discriminatory genetic typing-47 
methods[12–14] as well as statistical modelling[15], suggests patients with symptomatic CDI 48 
are not the only sources of infection and have pointed to the possible role of asymptomatic 49 
carriers. Therefore, any examination of the overall impact of vaccination needs to account for 50 
C. difficile transmission, including the potential role of asymptomatic carriers [14,16].  51 
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Previous studies have shown direct healthcare costs due to excess length of hospital 52 
stay to be the main driver of infection costs[17,18]. Hospital admissions from LTCF have 53 
been associated with increased risk of hospital-onset CDI[19] and residing in  LTCF was 54 
identified as an independent risk-factor for developing CDI[20]. Hence, this group of 55 
individuals are a potential target population for vaccination, as are patients with planned 56 
elective surgery who share many of the underlying risk factors  (frailty, hospital admission 57 
and antimicrobial usage) in common with the LTCF cohort [10]. Moreover, about 20% of 58 
CDI patients experience recurrent CDI[21], either due to re-infection or relapse[22], and 59 
primarily as a result of continued exposure to factors disturbing the gut flora post 60 
identification of CDI[23]. Therefore, patients with a history of CDI are a potential third target 61 
group for vaccination.   62 
Mathematical modelling is a well-established tool that can be used to extrapolate 63 
vaccination trial results to the population-level[24]. In the case of C. difficile, these methods 64 
would allow the exploration of the impact of vaccination, taking into account the different 65 
modes of acquisition[25], as well as the indirect effect of prevention of onward transmission. 66 
Therefore, a dynamic transmission model[26–37] was developed to investigate the 67 
effectiveness of four vaccination strategies, in terms of preventing CDI in a hospital-ward 68 
setting with patients at greater risk of acquiring the infection, such as the Intensive Care Unit 69 
(ICU)[38]. Although ICUs can vary markedly in their case mix, their critically ill status often 70 
causes a state of immunosuppression[39], and requires high levels of antimicrobial 71 
prescribing[40]. The model was designed to capture potential population-effects, as well as 72 
uncertainties related to the epidemiology of CDI, and is among the first to incorporate 73 
heterogeneous community populations. 74 
 75 
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Methods 76 
Model framework 77 
A discrete-time, individual-based dynamic transmission model[41] was developed, 78 
simulating the transmission and control of CDI in a 30-bed single ICU, serving a community 79 
of 100,000 individuals, over a five-year time period. Individual patient movements between 80 
the hospital, the surrounding community and  LTCF  were modelled (Figure 1). 81 
Transmission-events were explicitly simulated in the ICU, whereas patients could be 82 
admitted and re-admitted from the general community or LTCFs[42], each holding patients 83 
with different characteristics (Table 1). If a patient developed symptom-onset post-ICU 84 
discharge, the model captured this, however, onward-transmission in the community and 85 
LTCFs from these cases was not considered. Likewise, the time spent elsewhere in hospital 86 
(and thus the transmission elsewhere in hospital) prior to ICU admission and post-ICU 87 
discharge is not captured in the model. However, the importation rates of colonised and 88 
infected individuals (ai_ltcf, ac_ltcf, ai_com, ai_com) were informed by ICU admission data (Table 89 
1, Table S5), therefore we implicitly incorporated acquisition during the time spent elsewhere 90 
in hospital, as well as readmission of still colonised individuals from outside the hospital.  91 
Transmission process 92 
Patients with normal gut flora were assumed to be protected against C. difficile colonisation 93 
(compartment P, Figure 1). Although colonisation in healthy individuals with a normal gut 94 
flora has been reported, this is likely to be transient, with persistent colonisation among this 95 
group found to be rare [43–45]. Moreover, such healthy individuals are at a much lower risk 96 
of progressing to symptomatic disease. Consumption of ‘high risk’ antimicrobials (defined as 97 
broad-spectrum penicillins, cephalosporins, clindamycin, and quinolones) was assumed to 98 
result in susceptibility to colonisation (compartment S) because of their deleterious effect on 99 
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the microbiota [46]. Each day, susceptible patients (S) could become colonised with C. 100 
difficile through transmission, with the daily risk of colonisation (λt) increasing linearly with 101 
the number of transmitting CDI patients in the ICU ward (Table 1). The per day probability 102 
of colonisation, given at least one CDI or colonised patient on the ward, described the 103 
likelihood of transmission through direct contact between susceptible and infectious patients, 104 
and indirect contact between susceptible patients, contaminated staff and the environment. As 105 
vaccination is unlikely to affect the level of C. difficile carriage in the gastrointestinal tract, 106 
vaccinated and non-vaccinated colonised individuals were considered to contribute equally to 107 
the bacterium’s daily probability of colonisation. It was assumed that contacts (with patients, 108 
staff or the environment) occurred randomly and were homogenously distributed among 109 
patients.  110 
A proportion of patients can mount a natural immune response against C. difficile 111 
toxins, and are protected from infection[47]. Therefore, a distinction was made between 112 
patients that remained asymptomatic (compartment C) and those that suffered from CDI 113 
(compartment I) following an incubation period.  After successful treatment, patients lost 114 
their infection status but remained colonised with C. difficile. Colonisation status was lost 115 
after an average period of four weeks[48]. To simulate relapse whilst still colonised, the 116 
model allowed recovered patients to have another episode of CDI following successive 117 
antimicrobial use, but without transmission from another patient. Post-discharge, colonised 118 
patients recovered from C. difficile colonisation at a constant rate 1/c, where c is the average 119 
duration of colonisation [48,49] in days (Table 1). For individuals with onset post-discharge, 120 
this was 1/(s+c), with s representing the duration of symptomatic disease [12,50]. Finally, 121 
post-vaccination, patients were assumed protected from CDI, but not from 122 
colonisation[47,51]. For further model assumptions on bed occupancy, admission and 123 
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discharge dynamics and transmission dynamics in the community-settings see supplementary 124 
material. 125 
Interventions 126 
Compared to no vaccination, we simulated four strategies: 1) patients who have 127 
experienced an episode of CDI in the ward, at the time of discharge from the hospital, as they 128 
are at risk of experiencing recurrent infection; 2) LTCF residents in the catchment area of the 129 
hospital irrespective of whether they are to have planned elective surgery; 3) patients with 130 
planned elective surgery in the hospital catchment area and 4) all the above listed patient 131 
groups. The strategies involving LTCF residents and elective patients both concerned 132 
community-based strategies. All LTCF residents were assumed vaccinated and protected at 133 
the start of the simulation and for a period of two years after which a booster vaccine course 134 
was provided. Elective patients were vaccinated and protected pre-admission, assuming the 135 
time of their appointment being made allowed for enough time to receive vaccination and 136 
mount a successful immune response before hospital admission. Finally, ICU-patients that 137 
experienced CDI that hospital episode, were vaccinated at the time of hospital discharge, and 138 
assumed to be protected from that time onwards for a period of two years to represent waning 139 
immunity.  140 
Model parameterisation and validation 141 
 142 
Table 1 summarises the model parameter values. These values were derived from 143 
extensive analysis of national and regional healthcare data and peer-reviewed research 144 
articles otherwise. The transmission potential from symptomatic carriers (β1) and 145 
asymptomatic carriers  (β2) in English ICUs is largely unknown. Therefore we estimated 146 
these parameters by fitting the model output to CDI acquisition rates as reported in English 147 
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national ICU audit data [52]. Furthermore, we populated the model with national Hospital 148 
Episode statistics data on patient movements[53,54]. Model parameterisation is discussed in 149 
further detail in the supplementary material. We validated the model by comparing our model 150 
outputs to a list of targets based on external data sources, depicted in supplementary table S7. 151 
Scenario and sensitivity analysis 152 
Due to a lack of knowledge regarding  vaccine efficacy and the role of asymptomatic 153 
carriers in the transmission of C.difficle [14,16], scenario analysis was performed. This 154 
incorporated three levels of vaccine efficacy (1, 0.7 and 0.5) and three assumptions for 155 
asymptomatic transmission (where asymptomatic carriers transmitted at half the rate of 156 
symptomatic carriers (2:1), i.e. the “base case”; no asymptomatic transmission (1:0); and 157 
asymptomatic carriers transmitted as efficiently as symptomatic carriers (1:1), Table 2). 158 
Analysis of national data (described in more detail in previous publications [52,55]), showed 159 
that CDI acquisition rates and ward-based antimicrobial use varied nationally (Table S3). 160 
Therefore, two different levels of transmission (baseline and high) and three levels of 161 
antimicrobial use (baseline, low and high) were assumed. Here, the baseline scenarios 162 
represented the average acquisition and antimicrobial use rates in English hospitals as 163 
estimated from national data (Table S2)[40]. Combinations of the above listed possibilities 164 
were simulated as listed in Table 2. 165 
To account for parameter uncertainty (Table 1), probabilistic sensitivity analysis was 166 
performed using Latin hypercube sampling [56] as follows. One thousand random samples 167 
were drawn covering the whole range of possible values for each parameter equally and 168 
combined at random to create 1000 different parameter sets. As the model was stochastic, a 169 
different result could be expected for a given parameter set. Hence the medians of 100 170 
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simulation runs per parameter set were combined to obtain the overall median and 171 
interquartile range (IQR) of the model output encompassing parameter uncertainty.  172 
Model output  173 
The absolute reduction in number of cases per 1000 admissions for each strategy 174 
compared to a strategy without vaccination (strategy effectiveness) was evaluated, as well as 175 
the number of courses required to avert one case in the ICU (strategy efficiency).  176 
Results 177 
Simulation Results: Base Case Scenario 178 
No vaccination 179 
In the base-case  scenario, without vaccination (strategy 0), the median number of 180 
ICU-onset cases per 1000 admissions was 10.9 [IQR: 10.0 – 11.8] (Figure 2A). A majority of 181 
these cases (69%) were imported from outside the ICU. In total, 14.1 [13.2 – 15.0] ward-182 
acquired (symptomatic and asymptomatic) cases were observed per 1000 admissions (Figure 183 
2B). Seventy-nine per cent of acquisitions resulted in symptomatic infection (Figure 2B), but 184 
over half developed symptoms post ward discharge (57%), and thus remained asymptomatic 185 
whilst in the ICU.    186 
Vaccine programme effectiveness & efficiency  187 
Vaccinating all target populations (strategy 4) resulted in a 43% [IQR: 42 – 44] 188 
reduction in ICU-onset cases over five years, equal to 4.7 [4.3 – 5.1] CDI cases per 1000 189 
admissions (Table 3). Reviewing the strategies restricting vaccination to one target group, 190 
vaccinating all patients awaiting elective surgery (strategy 3) was the most effective. For all 191 
four strategies, vaccination prevented more imported cases than cases acquiring CDI within 192 
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the ICU (Table 3). This was particularly true for strategy 1 (vaccinating patients with a 193 
history of CDI) and 2 (LTCF residents). Strategy 2 proved the most efficient, i.e. required the 194 
lowest number of courses to avert one case of ICU-onset CDI in the base case scenario (13 195 
[11 – 16]), despite the low effectiveness of this strategy. In contrast, strategy 3 proved highly 196 
inefficient, requiring 146 [133 – 162] to prevent on case in the ICU (Table 3). 197 
Population-effect of the vaccine 198 
We assumed that vaccination did not provide direct protection against C. difficile 199 
colonisation. Therefore, vaccination is likely to result in an increase in asymptomatic cases. 200 
Indeed, the number of asymptomatic acquisitions did increase post-vaccination for strategy 2, 201 
3 and 4 (Figure 2B). However, as the drop in symptomatic infections was higher, the total 202 
number of acquisitions for these three strategies decreased, indicating a population-effect was 203 
present (Figure 2B). Of note, in the ICU alone, this meant that, post-vaccination, a reduction 204 
was observed in both symptomatic and asymptomatic acquisitions (Figure 2A) as without 205 
vaccination, a large fraction of patients would have developed symptoms post-discharge.  206 
Simulation Results: Scenario analysis 207 
 Cross transmission and antimicrobial use 208 
The ordering of the most effective and efficient strategies remained unchanged under 209 
all the simulated scenarios of transmission and antimicrobial use (Figure 3). All strategies 210 
proved most effective and efficient under scenarios of high transmission and high 211 
antimicrobial usage (scenario 6, Table S7). In particular, vaccination of elective patients 212 
(strategy 3) and therefore vaccination of all target groups (strategy 4) became more efficient, 213 
as they were most successful in preventing onward transmission (Figure 3). 214 
Impact of asymptomatic carriers 215 
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The comparative effectiveness and efficiency of each strategy also remained 216 
unchanged under different asymptomatic transmission assumptions. Post-vaccination, 217 
reduction in ward-based acquisition was greatest when asymptomatic carriers were not 218 
transmitting, and marginal when equal transmission between symptomatic and asymptomatic 219 
carriers was assumed (Figure S2). As a result, in the scenario without asymptomatic 220 
transmission, the marked decrease in ICU-acquisitions resulted in a reduction in 221 
asymptomatic carriers in- and also outside the ICU. Under the equal asymptomatic 222 
transmission assumption, vaccination resulted in a slight increase of asymptomatic carriers 223 
both in- as well as outside the ICU for the most effective strategies 3 and 4  (Figure S3).  224 
Impact of vaccine efficacy 225 
With vaccine efficacy reduced to 70% (scenario 7), vaccinating all target groups still 226 
averted 32% [31 – 33] of the ICU-onset CDI cases (Table S7). This was 24% [23 -25] when 227 
efficacy was as low as 50% (scenario 8). However, while the number of vaccine courses 228 
required for strategy 2 remained low even under our lowest vaccine efficacy scenario (23 [18 229 
– 32]), strategy 3 and 4 became very inefficient, with 281 [251 – 313] and 229 [206 – 255] 230 
courses required to prevent one case of CDI in the ICU  (Table S7). 231 
Discussion 232 
This study is the first dynamic-transmission model of different vaccination strategies 233 
against CDI in a high-risk hospital setting. We observed that immunising all three patient 234 
groups (LTCF residents, elective patients and patients with a history of ICU-onset CDI) could 235 
prevent up to 43% of CDI-onset cases in our simulated 30-bed ward. With ~17 CDI cases 236 
observed annually, representing current average incidence rates in English ICUs[52], this 237 
represented the prevention of ~7 ICU-onset cases per year. Of the three individual target 238 
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groups, vaccinating all patients awaiting elective surgery yielded the largest net reduction in 239 
ICU-onset cases.  240 
We did not conduct a formal cost-effectiveness evaluation, since costs are likely to be highly 241 
specific to a particular setting. However, we did consider efficiency – measured as the 242 
number of vaccination courses needed to prevent one case of CDI. In our study, the balance 243 
between ward-importations and ward-acquisitions of CDI drove the projected efficiency of 244 
vaccination. Previous statistical and molecular studies have questioned the importance of in-245 
hospital transmission from symptomatic patients in the development of CDI in endemic 246 
settings[12,13,15], and hint at other acquisition sources. The fitted model suggested that the 247 
majority (~70%) of ICU-onset cases were imported from outside the ICU. These importations 248 
were primarily asymptomatic admitted patients  who developed CDI following  antimicrobial 249 
treatment. As a result, the identification and targeting of patients groups at heightened risk of 250 
colonisation, became increasingly important when hospital-based CDI-onset was not 251 
primarily driven by hospital-based acquisitions. Vaccinating LTCF residents would be an 252 
example of such target populations [19,20]. We found that vaccinating LTCF residents 253 
proved highly efficient in terms of courses per case prevented (13 [11 – 16]), primarily as 254 
asymptomatic colonisation is frequent among the elderly residents of LTCF[57], and the high 255 
rates of antimicrobial prescribing in this group[58,59] compared to the rest of the population 256 
[60,61]. For the least efficient strategy, i.e. vaccinating elective surgery patients, this was 146 257 
[133 – 162]. To compare, for the human papilloma virus (HPV) vaccine, it is suggested that 258 
about 129 [62] up to 324 [63] young women will need to be vaccinated to prevent one case of 259 
cervical cancer, whereas for influenza in individuals >65 years old this is estimated to be 43 260 
(95% CI: 16–192) and as high as 3,333 (1,429–12,500) respectively [64]. Importantly, the 261 
low total number of admissions from LTCF means that this strategy only resulted in a small 262 
reduction in the overall reduction of cases in the ICU. Therefore, the proportion of 263 
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admissions from the LTCF is an important consideration in the generalisability of our 264 
findings. 265 
Our scenario analysis revealed that with lower levels of CDI-associated antimicrobial 266 
prescribing (e.g. clindamycin and cephalosporins), the efficiency of vaccination was greatly 267 
reduced, even under scenarios of high transmission rates, and the converse for high 268 
antimicrobial use was also true. Therefore, vaccination may be most efficient (and perhaps 269 
cost-effective) in settings where levels of broad-spectrum antimicrobial use are high and 270 
difficult to reduce.  271 
Another important finding we observed however is that, when asymptomatic carriers 272 
contributed to transmission, the number of colonisations outside the ICU increased following 273 
vaccination. These asymptomatic cases are more likely to remain undetected than 274 
symptomatic cases. When transmission from such individuals is present, this may lead to 275 
unintended consequences for the transmission of C. difficile and CDI incidence outside the 276 
ICU. When asymptomatic carriers were non-transmissible, this increase in colonisations was 277 
not present. Recently, a study by Durham and colleagues (2016) estimated that asymptomatic 278 
carriers transmitted at a 15 times reduced rate compared to CDI cases in a hospital-wide 279 
setting, as well as in the community[37]. Following our scenario analysis, this would suggest 280 
that the indirect effects of the vaccine might actually be higher than identified in our study 281 
under baseline assumptions of half the rate. Until we are more certain about the role of 282 
asymptomatic patients in the transmission of CDI in different settings, it is difficult to define 283 
the true effectiveness of vaccination, as well as any infection prevention control strategy.   284 
Only one previous modelling study by Lee et al, has quantified the impact of CDI 285 
vaccination in a comparative manner.  They found that a CDI vaccine will most likely be 286 
cost-effective in the United States when aimed at preventing recurrent CDI[65]. In our study, 287 
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vaccinating patients with a history of CDI (in the ICU) had close to no effect on CDI 288 
incidence in the ICU, and required ~80 courses to prevent one case. Lee and colleagues 289 
assumed that recurrent CDI would always occur in hospital or result in hospitalisation. In our 290 
model, active admission of recurrent cases was not incorporated; primarily because such 291 
patients are unlikely to be admitted to the ICU. We did incorporate readmission for other 292 
reasons however, and in the absence of vaccination, less than one case per 1000 admissions 293 
of the patients with a recurrent ICU-onset CDI was seen, either in the same episode or after 294 
re-admissions. This was for two reasons: firstly we observed a low number of relapses during 295 
the same hospital stay, secondly, the risk of ICU readmission when colonised was low, as the 296 
mean colonisation time, as observed by others (e.g. [34]) was approximately similar to the 297 
average number of days between ICU-admissions in England. Admittedly, our single-ward 298 
model framework did not include re-admission elsewhere in hospital, nor discharge to other 299 
hospital wards. Hence these constraints did not allow for a full investigation of this strategy. 300 
This study had several other limitations. The calculated number of vaccine courses for 301 
strategy 2, 3 and 4 are approximations, and in particularly for strategy 2, was likely to be an 302 
underestimate, as we did not account for the high mortality rates among LTCF residents and 303 
frequent new admissions to the cohort [66]. Secondly, due to the single-ward framework of 304 
our model, it is likely that we have underestimated the impact of vaccination: although we 305 
considered importations from and infection-onset post ICU discharge, our model only 306 
evaluated CDI-dynamics in the ICU. About 57% of the acquired C. difficile in the ICU 307 
developed onset after ICU-discharge. This is similar to estimates from active population-308 
based surveillance data from the United States revealing that ~63% of the healthcare-309 
associated CDI cases in 2011 developed symptoms in the community [67]. Onward 310 
transmission prevented from these cases with symptom-onset or recurrence outside the ICU 311 
was not captured, resulting in a potential underestimation of vaccine effectiveness in terms of 312 
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preventing hospital- as well as community-onset CDI. Incorporation of discharge and 313 
(re)admission dynamics elsewhere in the hospital may have improved the effectiveness of 314 
some strategies (notably vaccinating CDI cases) in preventing healthcare-onset CDI.  315 
However, data to more realistically inform such a holistic model would have required 316 
surveillance data on CDI occurrence in community-settings including the LTCF, which are 317 
currently lacking for most countries, including England, as is national-level data on ward 318 
movements and ward-specific CDI incidence rates. Therefore, any such model would have 319 
been highly theoretical and its results uncertain. Thirdly, our transmission parameters were 320 
estimated with all parameters at their baseline value, including antimicrobial use (i.e. the 321 
prevalence of usage of traditionally defined high-risk classes [46]).  Other classes  (e.g. 322 
macrolides) have been associated with CDI as well, albeit with much lower risks[46,68]. 323 
Inclusion of these classes, as well as their heterogeneity in associated CDI-risk, could 324 
potentially have resulted in a larger net-number of susceptible individuals at each ICU-day, 325 
resulting in lower fitted transmission rates, and subconsequently lower population-effects of 326 
the vaccine. As this would have affected the strategies involving elective patients and all 327 
patient groups in particular, we do not expect this would change our conclusions on the 328 
comparative performance of the strategies. Finally, our model did not explicitly consider the 329 
time required for seroconversion post-vaccination. All three vaccines under development are 330 
considering a 3-dose schedule covering a time period of ~30 days. The latest Phase II clinical 331 
trial data found seroconversion rates to peak at 60 days. With average waiting times for 332 
elective patients in England of ~70 days, this would support our assumption that elective 333 
patients were protected on admission. However, our mean time of ICU readmission was 30 334 
days, suggesting that our strategy involving patients with a history of CDI would have been 335 
even less effective when accounting for this preliminary findings on the timing of 336 
seroconversion. Once more data is available on the optimal dose regimen for the respective 337 
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vaccines, future modelling research should take both the seroconversion rate and dosing 338 
strategies in consideration. 339 
 340 
Conclusions 341 
Through careful modelling of the admission and discharge dynamics between 342 
healthcare and community settings, this study has provided useful insights as to how and 343 
where respective vaccination strategies involving different target groups are most likely to 344 
have an impact on CDI incidence rates. Vaccinating LTCF residents and elective patients 345 
may aid in preventing CDI in high-risk hospital settings such as the ICU. However, in 346 
settings with comparable ICU-acquisition and antimicrobial usage rates to England, this 347 
would require a high number of vaccine courses. Therefore, vaccination may be most useful 348 
in settings where IPC or reaching low levels of antimicrobial usage proves challenging. 349 
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Figure legends 
 
Figure 1: Model framework 
P = Patients protected from colonisation, hence infection; S = Patients susceptible to 
colonisation, hence infection; Cimm = Patients colonised with C. difficile that are protected 
from disease due to natural immunity or vaccination; Cn_imm= Patients colonised with C. 
difficile not protected from disease whilst failing to mount natural immunity or immunity 
following vaccination; I = Patients with CDI; LTCF = Long-term care facility  
Figure 2: Absolute number of cases averted per 1000 admissions shown for all four 
vaccination strategies; A) ICU-acquisitions and importations with onset in the ICU 
only; B) ICU-acquisitions with onset in- & outside the ICU. 
Model outcomes at baseline for strategy 0 (no vaccination); and number of cases averted 
under strategy 1 (CDI history); strategy 2 (LTCF residents); strategy 3 (elective patients) 
and strategy 4 (all combined). The middle line in the box represents the median difference of 
1000 model parameter sets between strategy 0 and each vaccination strategy, and upper and 
lower areas of the box indicate the seventy-fifth and twenty-fifth percentiles. 
Figure 3: Absolute number of imported and acquired cases averted per 1000 admissions 
in the ICU for the vaccination strategies under scenarios 1 to 6.  
Left panels: baseline transmission scenarios with A) Baseline; C) Low; E) High 
antimicrobial use. Right panels: high transmission transmission scenarios with B) 
Baseline; D) Low; F) High antimicrobial use. Black points: median absolute number ICU-
acquired cases averted (x-axis) and imported cases averted (y-axis) of the 1000 parameter 
sets under the different vaccination strategies.Transparent ellipses plot the 95% coverage 
intervals.  
 
Table legends 
Table 1: Model parameters and assumptions  
* Included in probabilistic sensitivity analysis; # Included in scenario analysis. PPS = Point 
prevalence survey data (reference provided refers to which point prevalence data); H= 
Individual hospital data; HES = Hospital Episode Statistics; A = Assumption, CQC = Care 
Quality Commission data 
Table 2: Simulated scenarios  
2:1 = asymptomatic carriers transmitted at half the rate of symptomatic carriers, the “base 
case”; 1:0 =  asymptomatic carriers did not spread C. difficile; 1:1 = asymptomatic carriers 
transmitted as efficiently as symptomatic carriers.   
Table 3: Number of ICU-onset cases averted per 1000 admissions and courses required 
to avert 1 case of ICU-onset CDI for strategies in the base case scenario 
Note NA: under some of the LHS parameter values, the CDI history strategy had no impact 
 
